University Hospital, Alexandroupolis
9
2
2
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
11%
1 trials in Phase 3/4
33%
1 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Measuring Small-Airways Disease Improvement After Step-up to Extrafine TRIple or High-dose ICS/LABA in Patients Uncontrolled on Medium Dose ICS/LABA eXploring T2 Inflammation
Role: collaborator
Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients
Role: lead
Artificial Intelligence for Automated Clinical Data Exploration From Electronic Medical Records (CardioMining-AI)
Role: collaborator
FEnofibRate as a Metabolic INtervention for COVID-19
Role: collaborator
Hellenic Registry of Ovation Alto™ Abdominal Stent Graft System
Role: collaborator
European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO
Role: collaborator
Is Self-transfusion Safe After Total Knee Arthroplasty in Terms of Nephrotoxicity of Gentamicin From Bone Cement?
Role: lead
Cangrelor Following Ticagrelor Loading vs Ticagrelor Loading Alone in STEMI
Role: collaborator
Aspiration of Subglottic Secretions Using Hi-Lo Evac Endotracheal Tube: Tube Size and Incidence of Suction Lumen Dysfunction
Role: lead
All 9 trials loaded